@article{LuuRiesterBaldrichetal.2021, author = {Luu, Maik and Riester, Zeno and Baldrich, Adrian and Reichardt, Nicole and Yuille, Samantha and Busetti, Alessandro and Klein, Matthias and Wempe, Anne and Leister, Hanna and Raifer, Hartmann and Picard, Felix and Muhammad, Khalid and Ohl, Kim and Romero, Rossana and Fischer, Florence and Bauer, Christian A. and Huber, Magdalena and Gress, Thomas M. and Lauth, Matthias and Danhof, Sophia and Bopp, Tobias and Nerreter, Thomas and Mulder, Imke E. and Steinhoff, Ulrich and Hudecek, Michael and Visekruna, Alexander}, title = {Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer}, series = {Nature Communications}, volume = {12}, journal = {Nature Communications}, doi = {10.1038/s41467-021-24331-1}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-309332}, year = {2021}, abstract = {Emerging data demonstrate that the activity of immune cells can be modulated by microbial molecules. Here, we show that the short-chain fatty acids (SCFAs) pentanoate and butyrate enhance the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells through metabolic and epigenetic reprograming. We show that in vitro treatment of CTLs and CAR T cells with pentanoate and butyrate increases the function of mTOR as a central cellular metabolic sensor, and inhibits class I histone deacetylase activity. This reprogramming results in elevated production of effector molecules such as CD25, IFN-γ and TNF-α, and significantly enhances the anti-tumor activity of antigen-specific CTLs and ROR1-targeting CAR T cells in syngeneic murine melanoma and pancreatic cancer models. Our data shed light onto microbial molecules that may be used for enhancing cellular anti-tumor immunity. Collectively, we identify pentanoate and butyrate as two SCFAs with therapeutic utility in the context of cellular cancer immunotherapy.}, language = {en} } @article{LockReimerPietrygaetal.2021, author = {Lock, Johan F and Reimer, Stanislaus and Pietryga, Sebastian and Jakubietz, Rafael and Flemming, Sven and Meining, Alexander and Germer, Christoph-Thomas and Seyfried, Florian}, title = {Managing esophagocutaneous fistula after secondary gastric pull-up: A case report}, series = {World Journal of Gastroenterology}, volume = {27}, journal = {World Journal of Gastroenterology}, doi = {10.3748/wjg.v27.i16.1841}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-369417}, pages = {1841-1846}, year = {2021}, abstract = {Background Gastric pull-up (GPU) procedures may be complicated by leaks, fistulas, or stenoses. These complications are usually managed by endoscopy, but in extreme cases multidisciplinary management including reoperation may be necessary. Here, we report a combined endoscopic and surgical approach to manage a failed secondary GPU procedure. Case summary A 70-year-old male with treatment-refractory cervical esophagocutaneous fistula with stenotic remnant esophagus after secondary GPU was transferred to our tertiary hospital. Local and systemic infection originating from the infected fistula was resolved by endoscopy. Hence, elective esophageal reconstruction with free-jejunal interposition was performed with no subsequent adverse events. Conclusion A multidisciplinary approach involving interventional endoscopists and surgeons successfully managed severe complications arising from a cervical esophago-cutaneous fistula after GPU. Endoscopic treatment may have lowered the perioperative risk to promote primary wound healing after free-jejunal graft interposition.}, language = {en} } @article{LiebersDuellFitzgeraldetal.2021, author = {Liebers, Nora and Duell, Johannes and Fitzgerald, Donnacha and Kerkhoff, Andrea and Noerenberg, Daniel and Kaebisch, Eva and Acker, Fabian and Fuhrmann, Stephan and Leng, Corinna and Welslau, Manfred and Chemnitz, Jens and Middeke, Jan-Moritz and Weber, Thomas and Holtick, Udo and Trappe, Ralf and Pfannes, Roald and Liersch, Ruediger and Spoer, Christian and Fuxius, Stefan and Gebauer, Niklas and Caill{\´e}, L{\´e}andra and Geer, Thomas and Koenecke, Christian and Keller, Ulrich and Claus, Rainer and Mougiakakos, Dimitrios and Mayer, Stephanie and Huettmann, Andreas and Pott, Christiane and Trummer, Arne and Wulf, Gerald and Brunnberg, Uta and Bullinger, Lars and Hess, Georg and Mueller-Tidow, Carsten and Glass, Bertram and Lenz, Georg and Dreger, Peter and Dietrich, Sascha}, title = {Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas}, series = {Blood Advances}, volume = {5}, journal = {Blood Advances}, doi = {10.1182/bloodadvances.2020004155}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-369173}, pages = {2707-2716}, year = {2021}, abstract = {The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1\%. The 6-month progression-free survival and overall survival (OS) was 27.7\% and 49.6\%, respectively. In the bridging cohort, 51.2\% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9\% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40\%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.}, language = {en} } @article{LeichSchrederPischimarovetal.2021, author = {Leich, Ellen and Schreder, Martin and Pischimarov, Jordan and St{\"u}hmer, Thorsten and Steinbrunn, Torsten and Rudelius, Martina and Br{\"u}nnert, Daniela and Chatterjee, Manik and Langer, Christian and Keppler, Sarah and Heredia-Guerrero, Sofia Catalina and Einsele, Hermann and Knop, Stefan and Bargou, Ralf Christian and Rosenwald, Andreas}, title = {Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma}, series = {Blood Cancer Journal}, volume = {11}, journal = {Blood Cancer Journal}, doi = {10.1038/s41408-021-00442-2}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-363410}, year = {2021}, abstract = {No abstract available.}, language = {en} } @article{LauruschkatPageEtteretal.2021, author = {Lauruschkat, Chris D. and Page, Lukas and Etter, Sonja and Weis, Philipp and Gamon, Florian and Kraus, Sabrina and Einsele, Hermann and Wurster, Sebastian and Loeffler, Juergen}, title = {T-Cell Immune Surveillance in Allogenic Stem Cell Transplant Recipients: Are Whole Blood-Based Assays Ready to Challenge ELISPOT?}, series = {Open Forum Infectious Diseases}, volume = {8}, journal = {Open Forum Infectious Diseases}, doi = {10.1093/ofid/ofaa547}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-363164}, year = {2021}, abstract = {We compared the feasibility of 4 cytomegalovirus (CMV)- and Aspergillus-reactive T-cell immunoassay protocols in allogenic stem cell transplant recipients. While enzyme-linked immunospot performed best overall, logistically advantageous whole blood-based assays performed comparably in patients with less severe lymphocytopenia. CMV-induced interferon-gamma responses correlated strongly across all protocols and showed high concordance with serology.}, language = {en} } @article{GilesGreenhalghDenesetal.2018, author = {Giles, James A. and Greenhalgh, Andrew D. and Denes, Adam and Nieswandt, Bernhard and Coutts, Graham and McColl, Barry W. and Allan, Stuart M.}, title = {Neutrophil infiltration to the brain is platelet-dependent, and is reversed by blockade of platelet GPIbα}, series = {Immunology}, volume = {154}, journal = {Immunology}, doi = {10.1111/imm.12892}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-233048}, pages = {322-328}, year = {2018}, abstract = {Neutrophils are key components of the innate immune response, providing host defence against infection and being recruited to non-microbial injury sites. Platelets act as a trigger for neutrophil extravasation to inflammatory sites but mechanisms and tissue-specific aspects of these interactions are currently unclear. Here, we use bacterial endotoxin in mice to trigger an innate inflammatory response in different tissues and measure neutrophil invasion with or without platelet reduction. We show that platelets are essential for neutrophil infiltration to the brain, peritoneum and skin. Neutrophil numbers do not rise above basal levels in the peritoneum and skin and are decreased (~60\%) in the brain when platelet numbers are reduced. In contrast neutrophil infiltration in the lung is unaffected by platelet reduction, up-regulation of CXCL-1 (2·4-fold) and CCL5 (1·4-fold) acting as a compensatory mechanism in platelet-reduced mice during lung inflammation. In brain inflammation targeting platelet receptor GPIbα results in a significant decrease (44\%) in platelet-mediated neutrophil invasion, while maintaining platelet numbers in the circulation. These results suggest that therapeutic blockade of platelet GPIbα could limit the harmful effects of excessive inflammation while minimizing haemorrhagic complications of platelet reduction in the brain. The data also demonstrate the ability to target damaging brain inflammation in stroke and related disorders without compromising lung immunity and hence risk of pneumonia, a major complication post stroke. In summary, our data reveal an important role for platelets in neutrophil infiltration to various tissues, including the brain, and so implicate platelets as a key, targetable component of cerebrovascular inflammatory disease or injury.}, language = {en} } @article{DuellLammersDjureticetal.2019, author = {Duell, Johannes and Lammers, Philip E. and Djuretic, Ivana and Chunyk, Allison G. and Alekar, Shilpa and Jacobs, Ira and Gill, Saar}, title = {Bispecific Antibodies in the Treatment of Hematologic Malignancies}, series = {Clinical Pharmacology \& Therapeutics}, volume = {106}, journal = {Clinical Pharmacology \& Therapeutics}, doi = {10.1002/cpt.1396}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226392}, pages = {781-791}, year = {2019}, abstract = {Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single-agent activity. Bispecific antibodies, however, redirect immune cells to the tumor for subsequent lysis, and preclinical and accruing clinical data support single-agent efficacy of these agents in hematologic malignancies, presaging an exciting era in the development of novel bispecific formats. This review discusses recent developments in this area, highlighting the challenges in delivering effective immunotherapies for patients.}, language = {en} } @phdthesis{Weis2024, author = {Weis, Philipp}, title = {Translationale Untersuchung zur Anwendung der durchflusszytometrischen Bestimmung \(Aspergillus\) \(fumigatus\) spezifischer T-Zellen in der Diagnostik von Aspergillosen}, doi = {10.25972/OPUS-37114}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-371145}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2024}, abstract = {Bei Patienten mit invasiver Aspergillose fanden sich gegen{\"u}ber gesunden Probanden deutlich erh{\"o}hte Werte A. fumigatus spezifischer CD154+/CD4+ Zellen. Die Anwendbarkeit dieses Assays im klinischen Routinebetrieb und bei gegen{\"u}ber A. fumigatus epxonierten Probanden und Patienten sollte in dieser translationalen Arbeit untersucht werden. F{\"u}r den vorbeschriebenen Assay zur Bestimmung CD154+/CD4+ Zellen aus aufgereinigten PBMCs zeigt diese Arbeit eine signifikant reduzierte Detektionsrate nach Blutprobenlagerung von {\"u}ber 2 Stunden. In der Literatur beschriebene Verfahren zur verl{\"a}ngerten Lagerungszeit von heparinisierten Blutproben mittels vorhergehender Dilution und Agitation erm{\"o}glichen keine Verl{\"a}ngerung pr{\"a}analytischer Lagerungszeiten {\"u}ber 6 Stunden. Die Kryokonservierung frisch aufbereiteter PBMCs bei -20 C vor Bestimmung A. fumigatus spezifischer T-Zellen wird als Versandm{\"o}glichkeit in einem multizentrischen Setting gezeigt. Um die klinische Anwendbarkeit zu verbessern, wird ein Vollblutprotokoll zur Detektion A. fumigatus spezifischer CD154+/CD4+ Zellen demonstriert, das die Verwendung von bettseitig mit Vollblut beimpften Blutmonovetten mit vorgelegtem A. fumigatus-Lysat erm{\"o}glicht. Die Anwendung des Assays zur Bestimmung A. fumigatus spezifischer T-Zellen wurde bei h{\"a}matoonkologischen Patienten vor und drei Monate nach Stammzelltransplantation untersucht. Insbesondere eine reduzierte Zellzahl der gemessenen Lymphozyten ist hier ein limitierender Faktor der erfolgreichen Messung. Aufgrund der generell nied- rigen Erfolgsrate von 20 \% bzw. 54 \% vor bzw. nach HSCT ist die Anwendbarkeit des Assays in diesem Kollektiv fraglich. Die Erhebung von Expositionsfaktoren gesunder Probanden gegen{\"u}ber A. fumigatus erm{\"o}glicht die Einteilung in eine schwach und stark gegen{\"u}ber A. fumigatus exponierte Gruppe mit signifikant erh{\"o}htem Anteil A. fumigatus spezifischer CD154+/CD4+ Zellen. Hierzu tr{\"a}gt insbesondere das Vorliegen antigenspezifischer T-Ged{\"a}chtniszellen als Korrelat einer langfristigen Exposition bei. Retrospektiv fand sich auch nach kurzfris- tiger beruflicher Exposition ein Anstieg CD154+/CD4+ spezifischer T-Zellen. Dies legt eine Verwendung CD154+/CD4+ spezifischer T-Zellen als Biomarker in Bereichen der umweltmedizinischen Abkl{\"a}rung von Schimmelpilzexposition oder der Diagnostik allergischer Erkrankungen nahe.}, subject = {Aspergillus fumigatus}, language = {de} } @article{KampfReiterBauer2018, author = {Kampf, Thomas and Reiter, Theresa and Bauer, Wolfgang Rudolf}, title = {An analytical model which determines the apparent T1 for Modified Look-Locker Inversion Recovery - Analysis of the longitudinal relaxation under the influence of discontinuous balanced (classical MOLLI) and spoiled gradient echo readouts}, series = {Zeitschrift f{\"u}r Medizinische Physik}, volume = {28}, journal = {Zeitschrift f{\"u}r Medizinische Physik}, doi = {10.1016/j.zemedi.2017.07.004}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-325498}, pages = {150-157}, year = {2018}, abstract = {Quantitative nuclear magnetic resonance imaging (MRI) shifts more and more into the focus of clinical research. Especially determination of relaxation times without/and with contrast agents becomes the foundation of tissue characterization, e.g. in cardiac MRI for myocardial fibrosis. Techniques which assess longitudinal relaxation times rely on repetitive application of readout modules, which are interrupted by free relaxation periods, e.g. the Modified Look-Locker Inversion Recovery = MOLLI sequence. These discontinuous sequences reveal an apparent relaxation time, and, by techniques extrapolated from continuous readout sequences, a putative real T1 is determined. What is missing is a rigorous analysis of the dependence of the apparent relaxation time on its real partner, readout sequence parameters and biological parameters as heart rate. This is provided in this paper for the discontinuous balanced steady state free precession (bSSFP) and spoiled gradient echo readouts. It turns out that the apparent longitudinal relaxation rate is the time average of the relaxation rates during the readout module, and free relaxation period. Knowing the heart rate our results vice versa allow to determine the real T1 from its measured apparent partner.}, language = {en} } @phdthesis{Mueller2024, author = {M{\"u}ller, Nicole}, title = {Modellierung klonaler Evolution beim Multiplen Myelom}, doi = {10.25972/OPUS-37081}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-370818}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2024}, abstract = {In dieser Arbeit wurde ein modulares Zelllinienmodell zur Visualisierung klonaler Evolutionsmechanismen etabliert. Hierf{\"u}r wurden unterschiedlich fluoreszierende Proteine (LSSmKate2, EGFP, mTagBFP2) durch Anwendung eines Sleeping Beauty basierten Vektorsystems in unterschiedliche Sublinien der Myelom Zelllinie L363 eingebracht. Diese vier Sublinien beinhalten jeweils eine von drei aus prim{\"a}ren Patientenproben gewonnenen Mutationen in IKZF1 (A152T, E170D, R439H) oder den IKZF1 WT. Die Anwendung von immunmodulatorischen Medikamenten (IMiDs) f{\"u}hrt zu einer Ubiquitinierung des Transkriptionsfaktors IKZF1 durch die E3-Ubiquitin-Protein-Ligase (CRBN-CUL4). Durch Mutationen in IKZF1 kommt es zu St{\"o}rungen in diesem Prozess und damit zu einer {\"U}berexpression von IKZF1. Dies wirkt sich wachstumsf{\"o}rdert auf die Myelomzellen aus. Die Auswirkungen der einzelnen Mutationen in IKZF1 ist aufgrund dessen ein klinisch relevantes Forschungsthema. In dieser Arbeit wurden jeweils zwei Sublinien mit Zellen des IKZF1 WT und Zellen mit einer IKZF1 Mutation mit jeweils unterschiedlich fluoreszierenden Proteinen markiert. Diese wurden gemeinsam unter Behandlung mit verschiedenen Konzentrationen von Lenalidomid inkubiert. Somit konnte das Selektionsverhalten mittels Durchflusszytometrie-Auswertungen visualisiert werden. Es konnte gezeigt werden, dass die IKZF1 Mutation A152T einen deutlichen Selektionsvorteil f{\"u}r die Myelomzellen darstellt. Bei den IKZF1 Mutationen E170D und R439H konnte kein Selektionsvorteil gegen{\"u}ber dem IKZF1 WT beobachtet werden.}, subject = {Lenalidomid}, language = {de} }